The clinical experience of macitentan in pulmonary hypertension in Indian cohort: 12-month follow-up
Open Access
- 1 January 2022
- journal article
- research article
- Published by Medknow in Lung India
- Vol. 39 (1), 12-15
- https://doi.org/10.4103/lungindia.lungindia_671_20
Abstract
Background: The effectiveness and safety of macitentan, an endothelin-receptor antagonist (ERA) in the treatment of pulmonary arterial hypertension (PAH), has been demonstrated in numerous randomized clinical trials including SERAPHIN, focused on the reduction of morbidity and mortality. Objectives: Our aim was to demonstrate the clinical and echocardiographic progression using macitentan in Indian patients with PAH. Settings and Design: It was a retrospective study of 20 patients with multiple etiologies of PAH who had begun macitentan in routine clinical practice from a single center. There were 55% of patients with existing PAH therapies. Subjects and Methods: The World Health Organization functional class (WHO-FC), 6-min walking distance, N-terminal prohormone of brain natriuretic peptide level (NT-pro-BNP), and echocardiographic data such as tricuspid annular plane systolic excursion (TAPSE), systolic pulmonary artery pressure (sPAP), and the occurrence of pericardial effusion were collected at baseline and 12-month follow-up. The statistical analysis was performed using SPSS software. Results: Of the 20 PAH patients, 70% were women. The majority were in WHO FC II (50%), while 35% were in FC III and 15% were in FC IV. The mean age was 43.4 years at the start of the therapy with macitentan. After 6 months of macitentan therapy, 85% showed substantial improvement in their FC, each increased its 6-min walking distance test (P < 0.0001), and there was a significant reduction in plasma levels of NT-pro BNP (P < 0.0001). There has also been an improvement in echocardiographic parameters such as TAPSE and sPAP (P < 0.0001). Conclusions: Our findings indicate that macitentan has been well tolerated and beneficial in Indian patients with PAH and further, future research is required to verify these results.Keywords
This publication has 13 references indexed in Scilit:
- Recommendations for the clinical management of patients receiving macitentan for pulmonary arterial hypertension (PAH): A Delphi consensus documentPulmonary Circulation, 2017
- Early Experience of Macitentan for Pulmonary Arterial Hypertension in Adult Congenital Heart DiseaseHeart, Lung and Circulation, 2017
- From bosentan to macitentan for pulmonary arterial hypertension and adult congenital heart disease: Further improvement?International Journal of Cardiology, 2016
- 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary HypertensionRevista Española de Cardiología (English Edition), 2016
- 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertensionEuropean Heart Journal, 2015
- Macitentan: An important addition to the treatment of pulmonary arterial hypertensionJournal of Pharmacology and Pharmacotherapeutics, 2015
- Macitentan: First Global ApprovalDrugs, 2013
- Macitentan and Morbidity and Mortality in Pulmonary Arterial HypertensionThe New England Journal of Medicine, 2013
- Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle CellsPLOS ONE, 2012
- Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor AntagonistThe Journal of pharmacology and experimental therapeutics, 2008